key: cord-1013044-94wrl96x
authors: Peters, Michael C.
title: Erratum: COVID-19–related Genes in Sputum Cells in Asthma: Relationship to Demographic Features and Corticosteroids
date: 2020-12-15
journal: Am J Respir Crit Care Med
DOI: 10.1164/rccm.v202erratum7
sha: ec78f3ce72028d7856d4d19f224ef12a3835aed7
doc_id: 1013044
cord_uid: 94wrl96x

nan

Our article, published in the July 1, 2020, issue of the Journal (1), contained an error in the number of healthy control subjects. The paper reported on 330 asthma participants in the SARP-3 (NHLBI Severe Asthma Research Program-3) cohort and 79 healthy control subjects (57 recruited by the University of California San Francisco [UCSF] Airway Clinical Research Center and 22 recruited by SARP-3). We recently discovered that a coding error resulted in sputum cell RNA from 47 mild asthma patients being included in the UCSF healthy subject group. To correct the error, we removed the 47 mild asthma patients and reanalyzed the data. After performing the reanalysis including the 22 healthy subjects from SARP and 10 healthy subjects from UCSF (total of 32 healthy controls) (revised Table 1 ), we found that our study conclusions remain the same. As illustrated in revised Figures 1 and 2 , sputum cell gene expression for COVID-19-related genes (ACE2 [angiotensin-converting enzyme 2] and TMPRSS2 [transmembrane protease serine 2]) are not significantly different in asthma and health (revised Figure 1A and 1B), and sputum cell gene expression for ACE2 and TMPRSS2 are significantly correlated with one another (revised Figure 2A) . The reanalysis shows that the P value for the increase in asthma for sputum cell ICAM1 expression (a comparator/control gene) compared with health increased from 0.005 to 0.09 (revised Figure 1C ). The main data for the paper, as originally presented in Figures 3 and 4 and which relied on data analyses that were restricted to the asthma cohort, do not need correction. We have made several additional changes throughout the article to reflect the corrected data. For the convenience of the readers, the Journal has replaced the online version of the article with a corrected version (a redlined version showing the changes may be accessed from the Supplements tag at the top of the HTML view of the article).

We apologize to the readership for these errors. n 

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma

Early use of inhaled corticosteroids in the emergency department treatment of acute asthma

Oral corticosteroid-dependent asthma: current knowledge and future needs

Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial

The use of benralizumab in the treatment of nearfatal asthma: a new approach

Risk factors for asthma exacerbation and treatment failure in adults and adolescents with well-controlled asthma during continuation and step-down therapy

A chronic obstructive pulmonary disease susceptibility gene, FAM13A, regulates protein stability of b-catenin

The Journal has been alerted to errors in two figures in the article by Jiang and colleagues (1), published in the July 15, 2016, issue.In Figure 1A , an incorrect image was used for the lower left panel (Rb IgG, Goat IgG). In addition, the panels in the bottom row included scale bars that were incorrectly labeled; these should be 20 mm instead of 40 mm. A corrected version of the figure is included here.In Figure E9B in the online supplement to the article, a duplicate image of the lower right panel (Fam13a 2/2 , PKF118-310) was inadvertently used for the lower left panel (Fam13a 1/1 , PKF118-310) . A revised version of Figure E9B is included here that includes the correct version of the lower left panel.The authors apologize to the Journal's readers for any confusion caused by these errors. n